Kiniksa Pharmaceuticals Ltd (KNSA) — Capital Reinvestment Ratio
Kiniksa Pharmaceuticals Ltd (KNSA) has a Capital Reinvestment Ratio of 0.01x as of June 2026, meaning it reinvests 0% of its operating cash flow ($47.46 Million) in capital expenditures ($663.00K). Check KNSA goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Kiniksa Pharmaceuticals Ltd Capital Reinvestment Ratio (2022–2025)
This chart tracks Kiniksa Pharmaceuticals Ltd's Capital Reinvestment Ratio across 4 annual periods. For the full cash flow conversion analysis, see Kiniksa Pharmaceuticals Ltd cash conversion from operations.
Annual Capital Reinvestment Ratio for Kiniksa Pharmaceuticals Ltd (2022–2025)
Year-by-year Capital Reinvestment Ratio for Kiniksa Pharmaceuticals Ltd from 2022 to 2025. See KNSA cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.01x | $25.69 Million | $277.00K | ▲ +0.0% |
| 2024 | 0.01x | $25.69 Million | $277.00K | ▲ +10.3% |
| 2023 | 0.01x | $13.30 Million | $130.00K | ▼ -45.9% |
| 2022 | 0.02x | $5.81 Million | $105.00K | — |